Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML

Hagop Kantarjian, Francis Giles, Susan O'Brien, Jorge Cortes, Oliver G. Ottmann, Lydia Wunderle, Barbara Wassmann, Dieter Hoelzer, Chiaki Tanaka, Paul Manley, Patricia Rae, William Mietlowski, Kathy Bochinski, Margaret Dugan, Leila Alland, Andreas Hochhaus, Kapil Bhalla, Maher Albitar, James D. Griffin

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML'. Together they form a unique fingerprint.